Back to search
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer trials you may qualify forThe purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-can…
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatmen…
Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in comb…
This is a first-in-human, Phase Ia/Ib, dose-escalation and expansion study evaluating the safety, pharmacokinetics, and activity of GDC-0587 (cyclin-dependent k…
The purpose of this trial is to estimate the recommended dose (RD) of \[177Lu\]Lu-NeoB in combination with ribociclib and fulvestrant in participants with estro…
This randomized phase II trial studies how well tamoxifen citrate works compared with z-endoxifen hydrochloride in treating patients with breast cancer that has…
A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women with ER Positive, HER2 Negative Advanced Breast Cancer (SERENA-1)